findmyKOL
Clinical trialNCT01505868CompletedPhase 1/PHASE2Interventional

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

SponsorM.D. Anderson Cancer CenterEnrollment170Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaLymphadenopathyMetastatic Prostate CarcinomaProstate AdenocarcinomaProstate Carcinoma Metastatic in the Bone+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Wayne State University/karmanos Cancer Institute

    Detroit, Michigan, United States

  • M D Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
11 Jul 2012
Primary completion
9 Dec 2019
Completion
9 Dec 2019
Last update posted
30 Jul 2021
Registered enrollment
170
Registry id
NCT01505868

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.